Meet
Miron Dilmanian

Research Scientist II

Miron Dilmanian supports clients by providing a unique perspective at the intersection of science, policy, and communications.

Prior to joining Avalere, Miron worked in the public relations and public affairs industry where he supported a range of healthcare clients, including pharmaceutical companies, trade associations, and non-profit organizations, working across a variety of therapeutic areas. Miron developed and implemented communications strategies to support science- and policy-related issues including advocacy, executive visibility, public health campaigns, and media relations.

Miron has a BS in neuroscience from University College London and an MS in integrative neuroscience from Georgetown University, where he focused on neurophysiology, primarily as it relates to mental health disorders.

Authored Content

September 16, 2024 | Insights & Analysis > Drug Pricing and Affordability

Commercial Spillover Impact of Part B Negotiations on Physicians
Physicians could lose at least $25 billion in add-on payments for 10 Part B drugs expected to be negotiated by CMS, with oncology products accounting for at least $12 billion.
April 3, 2024 | Insights & Analysis > Regulatory Strategy and FDA Policy

A More Complex Future Market for Diagnostics?
With regulatory changes on the horizon, diagnostics stakeholders should prepare for a new evidence development and commercialization environment.
November 3, 2023 | Insights & Analysis > Regulatory Strategy and FDA Policy

FDA Supply Chain and Quality Balancing Act: What’s Next?
The industry should expect and prepare for changes to regulatory oversight of drug supply chains and quality.
September 12, 2023 | Insights & Analysis > Drug Pricing and Affordability

Manufacturers Should Assess Wastage to Inform Mitigation Strategy
Manufacturers impacted by the Part B discarded drug refund policy should assess claims billing and adjudication patterns to inform mitigation strategy.
May 15, 2023 | Insights & Analysis > Regulatory Strategy and FDA Policy

Clinical and Market Differentiation of Combination Products
Combination products may offer differentiation but require consideration of unique decisions with regulatory and market access implications.
May 4, 2023 | Insights & Analysis > Cell and Gene Therapy

Pipeline Transformative Therapies May Require Payment Model Innovation
Avalere’s assessment highlights a diverse set of over 200 products in development that could challenge payment models across care settings and payers.
April 28, 2023 | Insights & Analysis > Regulatory Strategy and FDA Policy

Digital Health Technology Access Requires Early FDA, Payer Engagement
As digital health technologies evolve, manufacturers seek clarity on regulatory pathways and access channels.
October 25, 2022 | Insights & Analysis > Cell and Gene Therapy

Cell and Gene Therapy: Fundamental Development Questions for Sponsors
Cell and gene therapy (CGT) technology continues to outpace regulatory and reimbursement mechanisms, requiring sponsors to think proactively about development.
August 9, 2022 | Insights & Analysis > Regulatory Strategy and FDA Policy

FDA-CMS Collaboration: History and Future Outlook
FDA and CMS have historically had complementary roles, yet prior collaboration between the agencies generally has been limited.
July 27, 2022 | Insights & Analysis > Regulatory Strategy and FDA Policy

Ensuring Patient Access by Navigating Decisions at FDA and CMS
The FDA and CMS have historically had complementary roles. Recent activity highlights how their unique functions affect access to medicines.
March 15, 2022 | Insights & Analysis > Quality Improvement

Cancer Moonshot Highlights Opportunities to Improve Cancer Care
On February 2, 2022, President Biden announced a revitalization of the Obama-era Cancer Moonshot Initiative, including updated goals to reduce cancer deaths by at least 50% over the next 25 years and improve the experience of cancer survivorship for patients and their families.
March 8, 2022 | Insights & Analysis > Regulatory Strategy and FDA Policy

Advancing the Use of Digital Health Technologies
The digital health technologies (DHTs) market is projected to grow from $3.5 billion in 2020 to $23.5 billion by 2030. Stakeholders must navigate complex pathways as the FDA develops regulatory frameworks for DHTs.
February 3, 2022 | Insights & Analysis > Regulatory Strategy and FDA Policy

User Fee Amendment Reauthorization: What’s Next?
The first Congressional hearings for user fee reauthorization begin on February 3, 2022, and current legislative authority for UFAs will expire in September 2022.